6CWS

The NMR solution structure of CCL28

  • Classification: CYTOKINE
  • Organism(s): Homo sapiens
  • Expression System: Aphyosemion etsamense

  • Deposited: 2018-03-30 Released: 2018-07-04 
  • Deposition Author(s): Thomas, M.A., Peterson, F.C., Volkman, B.F.
  • Funding Organization(s): National Institutes of Health/National Institute Of Allergy and Infectious Diseases; National Institutes of Health/National Heart, Lung, and Blood Institute; National Institutes of Health/National Institute of General Medical Sciences 

Experimental Data Snapshot

  • Method: SOLUTION NMR
  • Conformers Calculated: 100 
  • Conformers Submitted: 20 
  • Selection Criteria: target function 

wwPDB Validation 3D Report Full Report


This is version 1.2 of the entry. See complete history

Literature

The Solution Structure of CCL28 Reveals Structural Lability that Does Not Constrain Antifungal Activity.

Thomas, M.A.He, J.Peterson, F.C.Huppler, A.R.Volkman, B.F.

(2018) J. Mol. Biol. 430: 3266-3282

  • DOI: 10.1016/j.jmb.2018.06.001

  • PubMed Abstract: 
  • The chemokine CCL28 is constitutively expressed in mucosal tissues and is abundant in low-salt mucosal secretions. Beyond its traditional role as a chemoattractant, CCL28 has been shown to act as a potent and broad-spectrum antimicrobial agent with p ...

    The chemokine CCL28 is constitutively expressed in mucosal tissues and is abundant in low-salt mucosal secretions. Beyond its traditional role as a chemoattractant, CCL28 has been shown to act as a potent and broad-spectrum antimicrobial agent with particular efficacy against the commensal fungus and opportunistic pathogen Candida albicans. However, the structural features that allow CCL28 to perform its chemotactic and antimicrobial functions remain unknown. Here, we report the structure of CCL28, solved using nuclear magnetic resonance spectroscopy. CCL28 adopts the canonical chemokine tertiary fold, but also has a disordered C-terminal domain that is partially tethered to the core by a non-conserved disulfide bond. Structure-function analysis reveals that removal of the C-terminal tail reduces the antifungal activity of CCL28 without disrupting its structural integrity. Conversely, removal of the non-conserved disulfide bond destabilizes the tertiary fold of CCL28 without altering its antifungal effects. Moreover, we report that CCL28 unfolds in response to low pH but is stabilized by the presence of salt. To explore the physiologic relevance of the observed structural lability of CCL28, we investigated the effects of pH and salt on the antifungal activity of CCL28 in vitro. We found that low pH enhances the antifungal potency of CCL28, but also that this pH effect is independent of CCL28's tertiary fold. Given its dual role as a chemoattractant and antimicrobial agent, our results suggest that changes in the salt concentration or pH at mucosal sites may fine-tune CCL28's functional repertoire by adjusting the thermostability of its structure.


    Organizational Affiliation

    Department of Biochemistry, Medical College of Wisconsin, Milwaukee, WI 53226, USA.,Department of Pediatrics, Division of Infectious Disease, Medical College of Wisconsin, Milwaukee, WI 53226, USA.,Department of Biochemistry, Medical College of Wisconsin, Milwaukee, WI 53226, USA. Electronic address: bvolkman@mcw.edu.




Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
C-C motif chemokine 28
A
108Homo sapiensMutation(s): 0 
Gene Names: CCL28 (SCYA28)
Find proteins for Q9NRJ3 (Homo sapiens)
Go to Gene View: CCL28
Go to UniProtKB:  Q9NRJ3
Experimental Data & Validation

Experimental Data

  • Method: SOLUTION NMR
  • Conformers Calculated: 100 
  • Conformers Submitted: 20 
  • Selection Criteria: target function 

Structure Validation

View Full Validation Report or Ramachandran Plots



Entry History & Funding Information

Deposition Data


Funding OrganizationLocationGrant Number
National Institutes of Health/National Institute Of Allergy and Infectious DiseasesUnited StatesR01 AI120655
National Institutes of Health/National Heart, Lung, and Blood InstituteUnited StatesF30 HL134253
National Institutes of Health/National Institute of General Medical SciencesUnited StatesT32 GM080202

Revision History 

  • Version 1.0: 2018-07-04
    Type: Initial release
  • Version 1.1: 2018-08-29
    Type: Data collection, Database references
  • Version 1.2: 2019-02-20
    Type: Author supporting evidence, Data collection